{
    "nctId": "NCT05622240",
    "briefTitle": "99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer",
    "officialTitle": "99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Dosimetric distribution of radiopharmaceuticals",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* patients in suspicion of breast cancer by mammography or ultrasonography,and being able to provide basic information and sign the written informed consent form\n\nExclusion Criteria:\n\n* The exclusion criteria included claustrophobia, pregnancy, breastfeeding, kidney or liver failure, inability to fulfill the study, and undergoing any preceding local or systemic therapies that might interfere with HER2 binding.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}